Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00616005 · ClinicalTrials.gov registry record · Phase 2
Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00616005 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 41 participants.
The verdict
NCT00616005, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
Objective: To determine activity of combo of Irinotecan + Temozolomide To further characterize any toxicity associated w combo of Irinotecan + Temozolomide
Interventions
- DRUG Temodar and Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2005-11 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00616005
The ClinicalTrials.gov registry entry for NCT00616005 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Temodar and Irinotecan is the first listed.
NCT00616005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00616005 about?
NCT00616005 is a clinical study titled "Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide". Objective: To determine activity of combo of Irinotecan + Temozolomide To further characterize any toxicity associated w combo of Irinotecan + Temozolomide
What is the current status of trial NCT00616005?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2005-11. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00616005?
The interventions under investigation include: Temodar and Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00616005?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.